Free Trial

AtriCure Q2 2023 Earnings Report

AtriCure logo
$31.50 -0.04 (-0.13%)
(As of 12/17/2024 ET)

AtriCure EPS Results

Actual EPS
-$0.12
Consensus EPS
-$0.27
Beat/Miss
Beat by +$0.15
One Year Ago EPS
-$0.32

AtriCure Revenue Results

Actual Revenue
$100.92 million
Expected Revenue
$97.55 million
Beat/Miss
Beat by +$3.37 million
YoY Revenue Growth
+19.40%

AtriCure Announcement Details

Quarter
Q2 2023
Time
After Market Closes

Conference Call Resources

Trump’s Secret Manhattan Project (Ad)

On January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just spent six months investigating this...and what I found is shocking.

Click here and I’ll show you exactly how to position your money

AtriCure Earnings Headlines

AtriCure, Inc. (NASDAQ:ATRC) Receives $42.00 Consensus PT from Analysts
Aethlon Medical (NASDAQ:AEMD) vs. AtriCure (NASDAQ:ATRC) Financial Survey
Do this Before Elon’s Reveal on January 22nd
Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.
AtriCure price target raised to $61 from $53 at Canaccord
See More AtriCure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like AtriCure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AtriCure and other key companies, straight to your email.

About AtriCure

AtriCure (NASDAQ:ATRC) develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

View AtriCure Profile

More Earnings Resources from MarketBeat

Upcoming Earnings